About TOLLEREBIO CORPORATION
TollereBio provides cutting-edge, cost-effective TLR adjuvants for vaccines using its proprietary BECC technology platform, enhancing both prophylactic and therapeutic vaccine efficacy. The company focuses on accessible and safe adjuvant solutions for global health needs.
Development of TLR adjuvants for prophylactic and therapeutic vaccinesEngineering of biosynthetic pathways for adjuvant designCreation of cost-effective vaccine adjuvantsNano-adjuvant delivery systems for vaccine antigens
Is this your company?
Claim TOLLEREBIO CORPORATION to unlock the federal & state contracts GovIntel's AI has matched to you right now — plus your own scored past-performance, who you're up against, and who's risky to team with.
Claim TOLLEREBIO CORPORATION & see your matchesFree to claim. Takes about a minute.
Data compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.